Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
62.844,00
-0,07%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ DiaMedica Therapeutics Inc (DMAC) DiaMedica Therapeutics Inc (DMAC) Notizie

DMAC

DiaMedica Therapeutics (DMAC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DMAC
DataOraFonteTitoloSimboloCompagnia
02/05/202414:55Business WireDiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024NASDAQ:DMACDiaMedica Therapeutics Inc
17/04/202422:08Business WireDiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic StrokeNASDAQ:DMACDiaMedica Therapeutics Inc
19/03/202421:15Business WireDiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial ResultsNASDAQ:DMACDiaMedica Therapeutics Inc
29/01/202422:13Business WireDiaMedica Therapeutics Announces Poster Presentation at International Stroke ConferenceNASDAQ:DMACDiaMedica Therapeutics Inc
23/01/202422:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
23/01/202422:12Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
22/01/202414:23Business WireDiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical OfficerNASDAQ:DMACDiaMedica Therapeutics Inc
13/11/202322:55Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DMACDiaMedica Therapeutics Inc
13/11/202322:52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DMACDiaMedica Therapeutics Inc
13/11/202322:28Business WireDiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial ResultsNASDAQ:DMACDiaMedica Therapeutics Inc
09/11/202314:25Business WireDiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023NASDAQ:DMACDiaMedica Therapeutics Inc
06/11/202314:23Business WireDiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023NASDAQ:DMACDiaMedica Therapeutics Inc
12/09/202314:13Business WireDiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology OfficerNASDAQ:DMACDiaMedica Therapeutics Inc
06/09/202314:35Business WireDiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth ConferenceNASDAQ:DMACDiaMedica Therapeutics Inc
14/08/202322:13Business WireDiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial ResultsNASDAQ:DMACDiaMedica Therapeutics Inc
08/08/202314:32Business WireDiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023NASDAQ:DMACDiaMedica Therapeutics Inc
18/07/202314:30Business WireDiaMedica Therapeutics to Attend the American Academy of Neurology Summer ConferenceNASDAQ:DMACDiaMedica Therapeutics Inc
10/07/202322:16Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:DMACDiaMedica Therapeutics Inc
10/07/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:DMACDiaMedica Therapeutics Inc
30/06/202322:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:DMACDiaMedica Therapeutics Inc
27/06/202322:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DMACDiaMedica Therapeutics Inc
27/06/202322:11Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:DMACDiaMedica Therapeutics Inc
26/06/202314:30Business WireDiaMedica Therapeutics Announces Closing of $37.5 Million Private PlacementNASDAQ:DMACDiaMedica Therapeutics Inc
23/06/202323:14Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:DMACDiaMedica Therapeutics Inc
21/06/202314:43Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:DMACDiaMedica Therapeutics Inc
21/06/202314:39Business WireDiaMedica Therapeutics Announces $37.5 Million Private PlacementNASDAQ:DMACDiaMedica Therapeutics Inc
21/06/202314:15Business WireDiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic StrokeNASDAQ:DMACDiaMedica Therapeutics Inc
30/05/202314:29Business WireDiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of DirectorsNASDAQ:DMACDiaMedica Therapeutics Inc
15/05/202322:28Business WireDiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial ResultsNASDAQ:DMACDiaMedica Therapeutics Inc
08/05/202314:50Business WireDiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023NASDAQ:DMACDiaMedica Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DMAC

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
STMMI
ST Microelectronics
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
TIT
Telecom Italia
BIT
SPM
Saipem
BIT
SRG
Snam
BIT
TEN
Tenaris
BIT
TRN
Terna Trasmissione Elett...
BIT
IVG
Iveco Group NV
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network